Appareil pulmonaire
AMG20200491 - DeLLPhi-301
A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Tarlatamab in Subjects With Relapsed/Refractory Small Cell Lung Cancer After Two or More Prior Lines of Treatment.
Paris
PAULINE DU RUSQUEC